MedTrace Logo

Ahmed Glaucoma Valve Alone, With Amniotic Membrane or With Mitomycin C (MMC) for Treatment of Refractory Glaucoma

NCT00893490 · Status: UNKNOWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2009-05-06

No results posted yet for this study

Summary

This randomized, controlled trial (RCT) compares the efficacy and safety of Ahmed Glaucoma Valve (AGV) implantation alone, with 3 minutes MMC application or with a single layer coverage of amniotic membrane. Outcomes include intraocular eye pressure (IOP), postoperative glaucoma medication and complications. AGV implantation site will be superior or inferior based on indication and these groups will be randomized separately.

Conditions

  • Refractory Glaucoma

Interventions

DEVICE

Ahmed Glaucoma Valve (AGV)

AGV implantation

DRUG

Mitomycin C (MMC)

3 minute MMC application

PROCEDURE

amniotic membrane coverage

single layer coverage of amniotic membrane

Sponsors & Collaborators

  • Shahid Beheshti University of Medical Sciences

    lead OTHER

Study Design

Purpose
TREATMENT

Eligibility

Min Age
7 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00893490 on ClinicalTrials.gov